# Celularity and DefEYE Partner on Exclusive License and Seed Investment for Regenerative Eye Care

> partnership · REPORTED · 2025-10-30

Celularity entered a strategic partnership with DefEYE, executing an exclusive license and pricing arrangement alongside an in-kind investment in DefEYE's $12 million Series Seed round. Celularity also became the exclusive contract manufacturer for DefEYE's ophthalmic biologics portfolio, which includes the Biovance franchise.

About DefEYE, Inc.: DefEYE is a privately held ophthalmic biologics company that develops decellularized placental-based tissue solutions for ocular surface disease, pterygium surgery, and other surgical eye care applications.

- Company: DefEYE
- Sector: medical_device
- Primary source: https://celularity.com/celularity-and-defeye-inc-partner-to-advance-growth-of-regenerative-therapies-in-eye-care/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.